title: Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases.
abstract: The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 micrograms/l was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.
authors.affiliation: Department of Gynecology and Obstetrics, S. Corona Hospital, Pietra Ligure, Italy.
authors.forename: G C
authors.initials: GC
authors.lastname: Torre
authors.forename: R
authors.initials: R
authors.lastname: Rembado
authors.forename: V
authors.initials: V
authors.lastname: Barbetti
authors.forename: G P
authors.initials: GP
authors.lastname: Vigliercio
authors.forename: M
authors.initials: M
authors.lastname: Foglia
authors.forename: A
authors.initials: A
authors.lastname: Calabrese
authors.forename: F
authors.initials: F
authors.lastname: Corongiu
mesh_terms: D000293:Adolescent; D000328:Adult; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005831:Genital Diseases, Female / Q000097:blood / Q000175:diagnosis*; D005833:Genital Neoplasms, Female / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012907:Smoking / Q000097:blood; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*
chemical_list: D014408:Biomarkers, Tumor; D014359:Trypsin Inhibitor, Kazal Pancreatic